

Mucopolysaccharidosis II (MPS II) (Hunter Syndrome) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

<https://marketpublishers.com/r/M4D68A0F9971EN.html>

Date: November 2022

Pages: 68

Price: US\$ 2,000.00 (Single User License)

ID: M4D68A0F9971EN

Abstracts

Mucopolysaccharidosis II (MPS II) (Hunter Syndrome) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Mucopolysaccharidosis II (MPS II) (Hunter Syndrome) - Drugs In Development, 2022, provides an overview of the Mucopolysaccharidosis II (MPS II) (Hunter Syndrome) (Genetic Disorders) pipeline landscape.

Mucopolysaccharidosis type II (MPS II), also known as Hunter syndrome, is a condition that affects many different parts of the body and occurs almost exclusively in males. Signs and symptoms include claw-like hands, protruding tongue, changing facial features, including thickening of the lips, tongue and nostrils and delayed development. Treatment includes bone marrow transplantation, enzyme therapy and gene therapy.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Mucopolysaccharidosis II (MPS II) (Hunter Syndrome) - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Mucopolysaccharidosis II (MPS II) (Hunter Syndrome) (Genetic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development

history and latest news and press releases.

The Mucopolysaccharidosis II (MPS II) (Hunter Syndrome) (Genetic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Mucopolysaccharidosis II (MPS II) (Hunter Syndrome) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 1, 2, 3, 1, 1, 6 and 2 respectively. Similarly, the Universities portfolio in Phase II and Phase I stages comprises 1 and 1 molecules, respectively.

Mucopolysaccharidosis II (MPS II) (Hunter Syndrome) (Genetic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

The pipeline guide provides a snapshot of the global therapeutic landscape of Mucopolysaccharidosis II (MPS II) (Hunter Syndrome) (Genetic Disorders).

The pipeline guide reviews pipeline therapeutics for Mucopolysaccharidosis II (MPS II) (Hunter Syndrome) (Genetic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration

details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Mucopolysaccharidosis II (MPS II) (Hunter Syndrome) (Genetic Disorders) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Mucopolysaccharidosis II (MPS II) (Hunter Syndrome) (Genetic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Mucopolysaccharidosis II (MPS II) (Hunter Syndrome) (Genetic Disorders)

REASONS TO BUY

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Mucopolysaccharidosis II (MPS II) (Hunter Syndrome) (Genetic Disorders).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Mucopolysaccharidosis II (MPS II) (Hunter Syndrome) (Genetic Disorders)

pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Contents

- Introduction
- Global Markets Direct Report Coverage
- Mucopolysaccharidosis II (MPS II) (Hunter Syndrome) - Overview
- Mucopolysaccharidosis II (MPS II) (Hunter Syndrome) - Therapeutics Development
- Pipeline Overview
- Pipeline by Companies
- Pipeline by Universities/Institutes
- Products under Development by Companies
- Products under Development by Universities/Institutes
- Mucopolysaccharidosis II (MPS II) (Hunter Syndrome) - Therapeutics Assessment
- Assessment by Target
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Mucopolysaccharidosis II (MPS II) (Hunter Syndrome) - Companies Involved in Therapeutics Development
- AngioChem Inc
- Apteeus SAS
- AVROBIO Inc
- Bioasis Technologies Inc
- Biorchestra Co Ltd
- Capsida Biotherapeutics Inc
- Denali Therapeutics Inc
- Esteve Pharmaceuticals SA
- GC Biopharma Corp
- Generium
- Homology Medicines Inc
- Immusoft Corp
- JCR Pharmaceuticals Co Ltd
- RegenxBio Inc
- ReqMed Co Ltd
- Sigilon Therapeutics Inc
- Mucopolysaccharidosis II (MPS II) (Hunter Syndrome) - Drug Profiles
- AVRRD-05 - Drug Profile
- Product Description
- Mechanism Of Action
- BMRD-001 - Drug Profile

Product Description
Mechanism Of Action
CAP-001 - Drug Profile
Product Description
Mechanism Of Action
DNL-310 - Drug Profile
Product Description
Mechanism Of Action
DUOC-01 - Drug Profile
Product Description
Mechanism Of Action
EGT-301 - Drug Profile
Product Description
Mechanism Of Action
Gene Therapy to Activate Iduronate 2 Sulfatase for Mucopolysaccharidosis II - Drug Profile
Product Description
Mechanism Of Action
GNR-055 - Drug Profile
Product Description
Mechanism Of Action
HMI-203 - Drug Profile
Product Description
Mechanism Of Action
idursulfase beta - Drug Profile
Product Description
Mechanism Of Action
ISP-002 - Drug Profile
Product Description
Mechanism Of Action
Mucopolysaccharidosis Type II - Drug Profile
Product Description
Mechanism Of Action
pabinafusp alfa - Drug Profile
Product Description
Mechanism Of Action
pentosan polysulfate sodium - Drug Profile
Product Description
Mechanism Of Action

Recombinant Iduronate 2-Sulfatase Replacement for Mucopolysaccharidosis II - Drug Profile

Product Description

Mechanism Of Action

RGX-121 - Drug Profile

Product Description

Mechanism Of Action

SIG-018 - Drug Profile

Product Description

Mechanism Of Action

xB-3008 - Drug Profile

Product Description

Mechanism Of Action

Mucopolysaccharidosis II (MPS II) (Hunter Syndrome) - Dormant Projects

Mucopolysaccharidosis II (MPS II) (Hunter Syndrome) - Discontinued Products

Mucopolysaccharidosis II (MPS II) (Hunter Syndrome) - Product Development

Milestones

Featured News & Press Releases

Sep 15, 2022: UK MHRA approves Avrobio's Phase I/II Hunter syndrome therapy trial

Jul 14, 2022: Avrobio receives orphan drug designation for Hunter syndrome gene therapy

Feb 15, 2022: JCR announces first patient dosed in phase 3 global clinical trial of JR-141 for treatment of MPS II (Hunter Syndrome)

Feb 10, 2022: Homology medicines announces presentations on HMI-203 investigational gene therapy for Hunter syndrome and broad applicability of AAVHSC platform for lysosomal storage disorders at the 18th Annual WORLDSymposium meeting

Feb 09, 2022: JCR pharmaceuticals to present posters on JR-141 at the 18th annual WORLDSymposium 2022

Feb 03, 2022: JCR Pharmaceuticals receives the WORLDSymposium new treatment award for IZCARGO (Pabinafusp Alfa)

Nov 29, 2021: Immusoft receives \$4M in funding from the California Institute for Regenerative Medicine (CIRM)

Nov 08, 2021: AVROBIO to present preclinical data on AVRRD-05 at the 14th ICIEM Conference

Nov 03, 2021: AVROBIO receives Rare Pediatric Disease Designation from the U.S. FDA for AVR-RD-05, a Gene Therapy for Mucopolysaccharidosis Type II (MPSII) or Hunter Syndrome

Nov 02, 2021: GC Green Cross designated as a European orphan drug for the

treatment of severe Hunter syndrome

Oct 20, 2021: Homology Medicines announces presentation of data supporting clinical programs in MPS II and PKU, including nonclinical and patient-focused research, at American Society of Human Genetics Meeting

Oct 18, 2021: Homology medicines initiates clinical trial for HMI-203, a one-time investigational gene therapy candidate for adults with MPS II (Hunter Syndrome)

Oct 18, 2021: JCR Pharmaceuticals Co : EMA grants PRIME designation for JR-141 for the treatment of Mucopolysaccharidosis type II (Hunter Syndrome)

Oct 15, 2021: JR-141 (Pabinafusp Alfa) for Hunter syndrome notice on the publication of a nonclinical and clinical evidence in International Journal of Molecular Sciences

Jul 29, 2021: JCR Pharmaceuticals announces presentation at 16th International Symposium on MPS and Related Diseases.

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List Of Tables

LIST OF TABLES

Number of Products under Development for Mucopolysaccharidosis II (MPS II) (Hunter Syndrome), 2022

Number of Products under Development by Companies, 2022

Number of Products under Development by Universities/Institutes, 2022

Products under Development by Companies, 2022

Products under Development by Companies, 2022 (Contd..1)

Products under Development by Universities/Institutes, 2022

Number of Products by Stage and Target, 2022

Number of Products by Stage and Mechanism of Action, 2022

Number of Products by Stage and Route of Administration, 2022

Number of Products by Stage and Molecule Type, 2022

Mucopolysaccharidosis II (MPS II) (Hunter Syndrome) - Pipeline by AngioChem Inc, 2022

Mucopolysaccharidosis II (MPS II) (Hunter Syndrome) - Pipeline by Apteus SAS, 2022

Mucopolysaccharidosis II (MPS II) (Hunter Syndrome) - Pipeline by AVROBIO Inc, 2022

Mucopolysaccharidosis II (MPS II) (Hunter Syndrome) - Pipeline by Bioasis Technologies Inc, 2022

Mucopolysaccharidosis II (MPS II) (Hunter Syndrome) - Pipeline by Biorchestra Co Ltd, 2022

Mucopolysaccharidosis II (MPS II) (Hunter Syndrome) - Pipeline by Capsida Biotherapeutics Inc, 2022

Mucopolysaccharidosis II (MPS II) (Hunter Syndrome) - Pipeline by Denali Therapeutics Inc, 2022

Mucopolysaccharidosis II (MPS II) (Hunter Syndrome) - Pipeline by Esteve Pharmaceuticals SA, 2022

Mucopolysaccharidosis II (MPS II) (Hunter Syndrome) - Pipeline by GC Biopharma Corp, 2022

Mucopolysaccharidosis II (MPS II) (Hunter Syndrome) - Pipeline by Generium, 2022

Mucopolysaccharidosis II (MPS II) (Hunter Syndrome) - Pipeline by Homology Medicines Inc, 2022

Mucopolysaccharidosis II (MPS II) (Hunter Syndrome) - Pipeline by Immusoft Corp, 2022

Mucopolysaccharidosis II (MPS II) (Hunter Syndrome) - Pipeline by JCR Pharmaceuticals Co Ltd, 2022

Mucopolysaccharidosis II (MPS II) (Hunter Syndrome) - Pipeline by RegenxBio Inc, 2022

Mucopolysaccharidosis II (MPS II) (Hunter Syndrome) - Pipeline by ReqMed Co Ltd, 2022

Mucopolysaccharidosis II (MPS II) (Hunter Syndrome) - Pipeline by Sigilon Therapeutics Inc, 2022

Mucopolysaccharidosis II (MPS II) (Hunter Syndrome) - Dormant Projects, 2022

Mucopolysaccharidosis II (MPS II) (Hunter Syndrome) - Discontinued Products, 2022

List Of Figures

LIST OF FIGURES

Number of Products under Development for Mucopolysaccharidosis II (MPS II) (Hunter Syndrome), 2022

Number of Products under Development by Companies, 2022

Number of Products under Development by Universities/Institutes, 2022

Number of Products by Stage and Top 10 Targets, 2022

Number of Products by Top 10 Mechanism of Actions, 2022

Number of Products by Stage and Top 10 Mechanism of Actions, 2022

Number of Products by Top 10 Routes of Administration, 2022

Number of Products by Stage and Top 10 Routes of Administration, 2022

Number of Products by Top 10 Molecule Types, 2022

Number of Products by Stage and Top 10 Molecule Types, 2022

I would like to order

Product name: Mucopolysaccharidosis II (MPS II) (Hunter Syndrome) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Product link: <https://marketpublishers.com/r/M4D68A0F9971EN.html>

Price: US\$ 2,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/M4D68A0F9971EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

